Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1141-1160 of 1,738 trials

Duchenne Muscular Dystrophy: SGT-003 Gene Therapy

We are studying a new gene therapy to see if it is safe and effective for males with Duchenne Muscular Dystrophy. The trial will assess improvements in muscle function and other health measures after a single intravenous dose.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Psoriatic Arthritis and Axial Spondyloarthritis: Sonelokimab Study

We are exploring how sonelokimab affects disease activity in patients with active psoriatic arthritis or axial spondyloarthritis. This study will help us understand its potential benefits and safety.

Axial SpondyloarthritisPsoriatic Arthritis3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineRheumatology

Erectile Dysfunction: Botulinum Toxin Injection Study

We are testing a new injection treatment for men with erectile dysfunction that hasn't improved with standard medications. The study will help us understand its effectiveness and any side effects.

Erectile Dysfunction6-12 monthsEfficacy phase (II)Standard MedicinesUrology

Systemic Sclerosis: Efgartigimod PH20 SC Study

We are testing a new treatment for adults with systemic sclerosis to see if it improves skin symptoms and overall health compared to a placebo. The study will also look at safety and how well the treatment works.

Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

APL-101 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, APL-101, for patients with advanced solid tumors, including non-small cell lung cancer with specific genetic mutations. The trial aims to assess its safety and effectiveness, as well as find the best dose.

Non-Small Cell Lung CancerCentral Nervous System NeoplasmSolid Tumors>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

B-Cell Lymphoma: TranspoCART19 T Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory B-cell lymphoma. The trial aims to evaluate the safety and effectiveness of this therapy in improving patient outcomes.

Relapsed or Refractory B-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Dexmedetomidine for Pain Management in Pediatric Surgery

We are studying whether adding intravenous dexmedetomidine to local anesthesia helps reduce pain after surgery in children. This trial will also look at how it affects recovery and any side effects.

Loco-regional Anesthesia in Pediatric Surgery6-12 monthsEfficacy phase (II)Standard MedicinesPartially RemoteInternal MedicineOtolaryngologyPediatrics

Focal Seizures: PRAX-628 Study

We are testing a new medication, PRAX-628, for adults with focal seizures to see if it can reduce seizure frequency compared to a placebo. The study also looks at the safety and tolerability of this treatment.

Focal EpilepsyEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Colon Cancer: New Treatment with PIPAC

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard treatments improves outcomes for patients with advanced colon cancer that has spread to the abdomen. This trial will help us understand its effects on survival and quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Hidradenitis Suppurativa: AVTX-009 Treatment Study

We are evaluating a new treatment, AVTX-009, for individuals with moderate to severe hidradenitis suppurativa. The goal is to see if it works better than a placebo and to check its safety.

Hidradenitis Suppurativa3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

Small Cell Lung Cancer: 68Ga-EVG321 Diagnostic Study

We are studying a new diagnostic agent to see how it spreads in the body of patients with small cell lung cancer. The trial also looks at its safety and how the body processes it.

Small Cell Lung Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Subarachnoid Hemorrhage: EDV2209 Medication Study

We are investigating the safety and tolerability of a new medication, EDV2209, for patients with bleeding in the brain. This study compares the effects of EDV2209 to a placebo to see how it may help in recovery.

Subarachnoid Hemorrhage>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineNeurology

Rheumatoid Arthritis and Sjogren's Disease: Rapcabtagene Autoleucel Study

We are evaluating the safety of a new treatment for people with difficult-to-treat rheumatoid arthritis and severe Sjogren's disease. The study also looks at how the treatment works in the body.

Rheumatoid ArthritisSjogren's DiseaseSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

Pancreatic Cancer: Durvalumab and Rintatolimod Combination

We are studying a new treatment combining durvalumab and rintatolimod for patients with metastatic pancreatic ductal adenocarcinoma. The goal is to see if this combination is safe and improves survival and quality of life.

Metastatic Pancreatic Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Sarcoidosis: Oral Sirolimus for Facial Skin Involvement

We are studying whether sirolimus can improve facial skin symptoms in patients with sarcoidosis. The trial also examines its effects on quality of life and overall skin health.

Skin Sarcoidosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesAllergologyDermatology

Progressive Multiple Sclerosis: IMU-838 Study

We are testing a new medication, IMU-838, to see if it helps reduce brain atrophy in patients with progressive multiple sclerosis. This study compares its effects to a placebo to evaluate its safety and tolerability.

Progressive Multiple Sclerosis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Seminomas: EDEN Study on Reduced Therapy

We are testing a less intense treatment for patients with stage IIa/IIb seminomas under 3 cm to see if it helps prevent relapse. We’re also evaluating a biomarker to understand treatment response and its effects on quality of life.

Stage IIa/IIb Seminoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology

Arrhythmogenic Cardiomyopathy: Atorvastatin Study

We are evaluating whether atorvastatin can help slow down heart function decline in people with Arrhythmogenic Cardiomyopathy. The study also looks at its safety and effects on heart-related markers.

Arrhythmogenic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Plaque Psoriasis: Bimekizumab vs. Topical Corticosteroids

We are studying whether bimekizumab can better control plaque psoriasis compared to standard topical treatments. This trial aims to improve disease management and quality of life for patients.

Eruptive Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Vaborem® for Serious Infections in Children

We are studying how Vaborem® is processed in the body and its safety in children with suspected or confirmed Gram-negative infections. This trial includes kids from birth to under 18 years old.

Acute Pyelonephritis≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPediatrics